ArticleJournal of medical biochemistry2020
Evaluation of urinary L-FABP as an early marker for diabetic nephropathy in type 2 diabetic patients.
Article in Journal of medical biochemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Performance of urinary liver-type fatty acid-binding protein in diabetic nephropathy: A meta-analysis.Frontiers in medicine · 2022Pooled it
- Biomarkers in Diabetic Kidney Disease: Early Detection, Prognostic Assessment, and Integration with Multi-Omics Signatures.Life (Basel, Switzerland) · 2026Review
- Urinary biomarkers in the early diagnosis of diabetic kidney disease and diabetic retinopathy: A pilot study.Journal of medical biochemistry · 2026Article
- Verification of the Utility of Urinary L-FABP as a Predictor of Impaired Renal Function Based on Its Relationship with Changes in Renal Function.Journal of clinical medicine · 2026Article
- Urinary biomarkers of diabetic kidney disease.World journal of diabetes · 2026Review
- Fetuin-A and Heme Oxygenase 1 as Potential New Markers in the Diagnosis of Diabetic Kidney Disease.International journal of molecular sciences · 2025Review
- Integrating Novel Biomarkers into Clinical Practice: A Practical Framework for Diagnosis and Management of Cardiorenal Syndrome.Life (Basel, Switzerland) · 2025Review
- Urinary L-FABP: A Novel Biomarker for Evaluating Diabetic Nephropathy Onset and Progression. A Narrative Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Review
- Augmented Intrarenal and Urinary Angiotensinogen in Diabetic Nephropathy: The Role of Isoflavones.International journal of molecular sciences · 2025Review
- Application of biomarkers in the diagnosis of kidney disease.Frontiers in medicine · 2025Review
- Urinary L-FABP Assay in the Detection of Acute Kidney Injury following Haematopoietic Stem Cell Transplantation.Journal of personalized medicine · 2024Article
- Association between continuous glucose monitoring-derived glycemic control indices and urinary biomarkers of diabetic kidney disease: Hyogo Diabetes Hypoglycemia Cognition Complications study.Acta diabetologica · 2024Article
- Lipid metabolism disorder in diabetic kidney disease.Frontiers in endocrinology · 2024Review
- Urinary Liver-Type Fatty Acid Binding Protein, a Biomarker for Disease Progression, Dialysis and Overall Mortality in Chronic Kidney Disease.Journal of personalized medicine · 2023Article
- Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease.Nature reviews. Nephrology · 2023Review
- Association of urinary liver-type fatty acid-binding protein with renal functions and antihyperglycemic drug use in type 2 diabetic nephropathy patients.International urology and nephrology · 2023Observational
- Parameters influencing renal response to SGLT2 inhibitors and GLP1 receptor agonists in type 2 diabetes patients with preserved renal function: a comparative, prospective study.Journal of endocrinological investigation · 2023Article
- Endogenous markers of kidney function and renal drug clearance processes of filtration, secretion, and reabsorption.Current opinion in toxicology · 2022Article
- Early renal structural changes and potential biomarkers in diabetic nephropathy.Frontiers in physiology · 2022Review
- Serum Albumin in Health and Disease: Esterase, Antioxidant, Transporting and Signaling Properties.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlbuminuria is the standard biomarker for the diagnosis of diabetic nephropathy (DN). However, some patients with persistent microalbuminuria still progress to chronic kidney disease, raising the question of finding a better biomarker. This study aimed to evaluate the correlation of urinary liver-type fatty acid-binding protein (L-FABP) levels with renal function and to compare the role of urinary albumin-to-creatinine ratio (ACR) with urinary L-FABP in early detection of DN in type 2 diabetic patients.
methodsThe cross-sectional study was done on 106 type 2 diabetic patients and 30 non-diabetic people. L-FABP was measured with the Latex enhanced immunoturbidimetric technique.
resultsThere was a strong and negative correlation between the urine L-FABP levels and eGFR (r = -0.606, p<0.001). The urinary L-FABP levels were significantly higher (p<0.001) in the normoalbuminuria diabetic group than the non-diabetic control group. The ROC-curve analyses in the diabetic patients and the normoalbuminuria diabetic patients showed that the AUCL-FABP was remarkably higher (p<0.001) than the AUCACR. An optimal cutoff value of 5 mg L-FABP/g Cr (with the sensitivity of 98.1% and specificity of 90%) and of 4.3 mg L-FABP/g Cr (with the sensitivity of 100% and specificity of 86.67%) was set to detect DN in the diabetic patients and the normoalbuminuria diabetic patients, respectively.
conclusionsThe change in urinary L-FABP levels happened earlier than in urinary albumin during renal function impairment. Urinary L-FABP can be used as a better indicator than ACR for early detection of DN in type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.